Yes, but not holding my breath though....
"ImpediMed is subject to the Australian Securities Exchange's continuous disclosure rules, which are governed by the ASX Listing Rules, particularly Listing Rule 3.1. This rule mandates that ASX-listed companies must immediately disclose any information that could have a "material effect" on the share price to the ASX and thus to the public. This means they cannot withhold material information, such as major sales updates or significant new contracts, until the AGM if it could influence investor decisions."
Thank you ChatGPT.
That being said, is there are upcoming things in the pipeline this might help steady the ship.
Add to My Watchlist
What is My Watchlist?
